A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty

Figures & data

Table 1 Baseline and surgical characteristics of study subjects and eyes

Subjects	Subjects n (%) n=204
Age, mean, years (SD)	71.6 (11.3)
Range	18–93
Sex, n (%)
Male	97 (47.5)
Female	107 (52.5)
Race, n (%)
Caucasian	137 (70.3)
African American	34 (17.4)
Native American	17 (8.7)
Hispanic	6 (3.1)
Asian	1 (0.5)
Surgical eye, n (%)
OD only	83 (40.7)
OS only	63 (30.9)
OU	58 (28.4)
Eyesa	Eyes n (%) n=262
Glaucoma diagnosisb
POAG	128 (49.8)
POAG, NSC	108 (42.0)
PXG, NSC	8 (3.1)
PXG	4 (1.6)
Pigmentary glaucoma	2 (0.8)
Ocular hypertension	2 (0.8)
Otherc	5 (1.9)
Suture tension,d n (%)
Yes	236 (90.8)
No	24 (9.2)
Phaco IOL
Yes	124 (47.3)
No	138 (52.7)

Notes:

a Data not available for all characteristics for all eyes.

b Missing for five eyes.

c Other includes one case each of chronic angle-closure glaucoma with nuclear sclerotic cataract; inflammatory glaucoma; juvenile-onset open-angle glaucoma; mixed mechanism glaucoma with nuclear sclerotic cataract; pigmentary glaucoma with nuclear sclerotic cataract.

d Missing for 2 eyes.

Abbreviations: IOL, intraocular lens; NSC, nuclear sclerotic cataract; OD, right eye; OS, left eye; OU, both eyes; POAG, primary open-angle glaucoma; PXG, pseudoexfoliative glaucoma.

Table 2 Dosing frequency for LE suspension 0.5% over the first 3 month of postcanaloplasty

Time point	Eyes receiving LE postoperatively (%)
	Day 1 (n=262) n (%)	Week 1 (n=255) n (%)	Month 1 (n=244) n (%)	Month 3 (n=210) n (%)
Totala	261 (99.6)	253 (99.2)	119 (48.8)	2 (1.4)
Individual dosing frequenciesb
QD	0 (0)	2 (0.8)	78 (65.5)	0 (0)
BID	3 (1.1)	34 (13.4)	23 (19.32)	2 (66.7)
TID	7 (2.7)	133 (52.6)	11 (9.24)	0 (0)
QID	241 (92.3)	79 (31.2)	6 (5.04)	1 (33.3)
6×/day	9 (3.4)	5 (2.0)	0 (0)	0 (0)
Not specified	1 (0.5)	0 (0)	1 (0.8)	0 (0)

Notes:

a Total expressed as the percentage of all included eyes.

b Dosing frequency expressed as percentage of total eyes that received LE.

Abbreviation: LE, loteprednol etabonate.

Table 3 Inflammation grading for AC cells and AC flare by postoperative visit

Visit	Eyes, n	AC cells or flare grade, n (%) eyes
		0	0.5	1	2	3	4
AC cells
Day 1	259	173 (66.8)	32 (12.4)	36 (13.9)	13 (5.0)	3 (1.2)	2 (0.8)
Week 1a	255	202 (79.2)	23 (9.0)	16 (6.3)	10 (3.9)	3 (1.2)	0
Month 1	244	223 (91.4)	10 (4.1)	8 (3.3)	3 (1.2)	0	0
Month 3	210	209 (99.5)	0	0	1 (0.5)	0	0
AC flare
Day 1	259	234 (90.4)	2 (0.8)	22 (8.5)	1 (0.4)	0	0
Week 1	255	233 (91.4)	8 (3.1)	12 (4.7)	1 (0.4)	1 (0.4)	0
Month 1	244	238 (97.0)	1 (0.4)	5 (2.1)	0	0	0
Month 3	210	209 (99.5)	0	1 (0.5)	0	0	0

Notes:

a One eye graded as unknown at week 1. Graded on a scale of 0, 0.5, 1, 2, 3, or 4.

Abbreviation: AC, anterior chamber.

Figure 1 Mean intraocular pressure in eyes treated with LE suspension 0.5% postcanaloplasty.

Notes: *P<0.001 vs baseline. n, number of subjects with evaluable data at each time point.
Abbreviations: IOP, intraocular pressure; LE, loteprednol etabonate.

Figure 2 Intraocular pressure-lowering medication use following canaloplasty.

Notes: *P<0.001 vs baseline. n, number of subjects with evaluable data at each time point.
Abbreviation: IOP, intraocular pressure.

Table 4 Completea and qualifiedb surgical success rates (%) at postoperative month 6, month 12, year 2, and year 3

Success category	Postoperative time point
	Month 6 (n=170)	Month 12 (n=153)	Month 18 (n=139)	Month 24 (n=118)	Month 36 (n=41)
Complete success (%)a
≤21 mmHg	78.8	67.3	62.6	66.1	63.4
≤18 mmHg	69.4	62.8	59.0	60.2	61.0
≤15 mmHg	51.2	47.7	45.3	48.3	53.7
Qualified success (%)b
≤21 mmHg	90.6	95.4	92.8	92.4	92.7
≤18 mmHg	78.2	84.3	81.3	84.8	82.9
≤15 mmHg	56.5	62.1	59.7	69.5	70.7

Notes:

a No use of IOP-lowering medication.

b Use of ≤2 (including 0) IOP-lowering medications.

Abbreviation: IOP, intraocular pressure.